Assessment of the effect of potential antifibrotic compounds on total and αVβ6 integrin-mediated TGF-β activation

Pharmacology Research and Perspectives

Volumn 2, Issue 4, 2014, Pages

  Porte, Joanne ^a   Jenkins, Gisli ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Idiopathic pulmonary fibrosis; integrin; transforming growth factor

Indexed keywords

ANTIFIBROTIC AGENT; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; GLUCOCORTICOID RECEPTOR; INTEGRIN; PIRFENIDONE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROGENESIS; FLOW CYTOMETRY; GENE EXPRESSION; GENE SYNTHESIS; HIGH THROUGHPUT SEQUENCING; LUNG FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION;

EID: 84979983271     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.30     Document Type: Article

References (54)

1. Abe M., Harpel J. G., Metz C. N., Nunes I., Loskutoff D. J., Rifkin D. B. (1994). An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 216: 276–284.
2. Annes J. P., Munger J. S., Rifkin D. B. (2003). Making sense of latent TGFbeta activation. J Cell Sci 116: 217–224.
3. Azuma A. (2012). Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 6: 107–114.
4. Borgstrom L., Kagedal B., Paulsen O. (1986). Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31: 217–222.
5. Broekelmann T. J., Limper A. H., Colby T. V., McDonald J. A. (1991). Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 88: 6642–6646.
6. Brown P. D., Wakefield L. M., Levinson A. D., Sporn M. B. (1990). Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Growth Factors 3: 35–43.
7. Burghardt I., Tritschler F., Opitz C. A., Frank B., Weller M., Wick W. (2007). Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun 354: 542–547.
8. Cho M. E., Kopp J. B. (2010). Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs 19: 275–283.
9. Crawford S. E., Stellmach V., Murphy-Ullrich J. E., Ribeiro S. M., Lawler J., Hynes R. O., et al. (1998). Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93: 1159–1170.
10. Dasch J. R., Pace D. R., Waegell W., Inenaga D., Ellingsworth L. (1989). Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol 142: 1536–1541.
11. Demedts M., Behr J., Buhl R., Costabel U., Dekhuijzen R., Jansen H. M., et al. (2005). High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353: 2229–2242.
12. Denton C. P., Merkel P. A., Furst D. E., Khanna D., Emery P., Hsu V. M., et al. (2007). Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 56: 323–333.
13. Felton V. M., Borok Z., Willis B. C. (2009). N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol 297: L805–L812.
14. Fontana L., Chen Y., Prijatelj P., Sakai T., Fassler R., Sakai L. Y., et al. (2005). Fibronectin is required for integrin alphavbeta6-mediated activation of latent TGF-beta complexes containing LTBP-1. FASEB J 19: 1798–1808.
15. Gribbin J., Hubbard R. B., Le Jeune I., Smith C. J., West J., Tata L. J. (2006). Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61: 980–985.
16. Grygielko E. T., Martin W. M., Tweed C., Thornton P., Harling J., Brooks D. P., et al. (2005). Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 313: 943–951.
17. Hahm K., Lukashev M. E., Luo Y., Yang W. J., Dolinski B. M., Weinreb P. H., et al. (2007). Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 170: 110–125.
18. Hilberg F., Roth G. J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., et al. (2008). BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68: 4774–4782.
19. Hisatomi K., Mukae H., Sakamoto N., Ishimatsu Y., Kakugawa T., Hara S., et al. (2012). Pirfenidone inhibits TGF-beta1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm Med 12: 24.
20. Horan G. S., Wood S., Ona V., Li D. J., Lukashev M. E., Weinreb P. H., et al. (2008). Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 177: 56–65.
21. Iyer S. N., Gurujeyalakshmi G., Giri S. N. (1999). Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 291: 367–373.
22. Jenkins G (2013). Pirfenidone should be prescribed for patients with idiopathic pulmonary fibrosis. Thorax 68:603–608.
23. Jenkins G., Blanchard A., Borok Z., Bradding P., Ehrhardt C., Fisher A., et al. (2012). In search of the fibrotic epithelial cell: opportunities for a collaborative network. Thorax 67: 179–182.
24. Jobling M. F., Mott J. D., Finnegan M. T., Jurukovski V., Erickson A. C., Walian P. J., et al. (2006). Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res 166: 839–848.
25. Laping N. J., Everitt J. I., Frazier K. S., Burgert M., Portis M. J., Cadacio C., et al. (2007). Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 13: 3087–3099.
26. Lavrentiadou S. N., Chan C., Kawcak T., Ravid T., Tsaba A., van der Vliet A., et al. (2001). Ceramide-mediated apoptosis in lung epithelial cells is regulated by glutathione. Am J Respir Cell Mol Biol 25: 676–684.
27. Liu R. M., Gaston Pravia K. A. (2010). Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radical Biol Med 48: 1–15.
28. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095–2128.
29. Lyons R. M., Keski-Oja J., Moses H. L. (1988). Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol 106: 1659–1665.
30. Ma L. J., Yang H., Gaspert A., Carlesso G., Barty M. M., Davidson J. M., et al. (2003). Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice. Am J Pathol 163: 1261–1273.
31. Mross K., Stefanic M., Gmehling D., Frost A., Baas F., Unger C., et al. (2010). Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 16: 311–319.
32. Mu D., Cambier S., Fjellbirkeland L., Baron J. L., Munger J. S., Kawakatsu H., et al. (2002). The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. J Cell Biol 157: 493–507.
33. Munger J. S., Huang X., Kawakatsu H., Griffiths M. J., Dalton S. L., Wu J., et al. (1999). The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319–328.
34. Nakayama S., Mukae H., Sakamoto N., Kakugawa T., Yoshioka S., Soda H., et al. (2008). Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 82: 210–217.
35. Navaratnam V., Fleming K. M., West J., Smith C. J., Jenkins R. G., Fogarty A., et al. (2011). The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 66: 462–467.
36. Neurohr C., Nishimura S. L., Sheppard D. (2006). Activation of transforming growth factor-beta by the integrin alphavbeta8 delays epithelial wound closure. Am J Respir Cell Mol Biol 35: 252–259.
37. Popov Y., Patsenker E., Stickel F., Zaks J., Bhaskar K. R., Niedobitek G., et al. (2008). Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 48: 453–464.
38. Puthawala K., Hadjiangelis N., Jacoby S. C., Bayongan E., Zhao Z., Yang Z., et al. (2008). Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 177: 82–90.
39. Rubino C. M., Bhavnani S. M., Ambrose P. G., Forrest A., Loutit J. S. (2009). Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 22: 279–285.
40. Shi S., Wu J., Chen H., Zeng F. (2007). Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol 47: 1268–1276.
41. Shi M., Zhu J., Wang R., Chen X., Mi L., Walz T., et al. (2011). Latent TGF-beta structure and activation. Nature 474: 343–349.
42. Shihab F. S., Bennett W. M., Yi H., Andoh T. F. (2002). Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2: 111–119.
43. Sime P. J., Xing Z., Graham F. L., Csaky K. G., Gauldie J. (1997). Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Investig 100: 768–776.
44. Song C. Z., Tian X., Gelehrter T. D. (1999). Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci USA 96: 11776–11781.
45. Sullivan B. P., Weinreb P. H., Violette S. M., Luyendyk J. P. (2010). The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol 177: 2837–2849.
46. Taipale J., Koli K., Keski-Oja J. (1992). Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem 267: 25378–25384.
47. Tatler A. L., Porte J., Knox A., Jenkins G., Pang L. (2008). Tryptase activates TGFbeta in human airway smooth muscle cells via direct proteolysis. Biochem Biophys Res Commun 370: 239–242.
48. Thomas M., Docx C., Holmes A. M., Beach S., Duggan N., England K., et al. (2009). Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol 174: 380–389.
49. Wang Q., Wang Y., Hyde D. M., Gotwals P. J., Koteliansky V. E., Ryan S. T., et al. (1999). Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 54: 805–812.
50. Wang B., Dolinski B. M., Kikuchi N., Leone D. R., Peters M. G., Weinreb P. H., et al. (2007). Role of alphavbeta6 integrin in acute biliary fibrosis. Hepatology 46: 1404–1412.
51. Weinreb P. H., Simon K. J., Rayhorn P., Yang W. J., Leone D. R., Dolinski B. M., et al. (2004). Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes. J Biol Chem 279: 17875–17887.
52. Wipff P. J., Rifkin D. B., Meister J. J., Hinz B. (2007). Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 179: 1311–1323.
53. Xu M. Y., Porte J., Knox A. J., Weinreb P. H., Maher T. M., Violette S. M., et al. (2009). Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 174: 1264–1279.
54. Yang Y., Ye Y., Lin X., Wu K., Yu M. (2013). Inhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transition of human lens epithelial cells line SRA01/04. PLoS ONE 8: e56837.